Citations

Clear

439 citation(s) found for "Stone, M".

In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46
Wang, Hongjie , Liu, Ying , Li, Zong-Yi, Tuve, Sebastian, Stone, Daniel , Kalyushniy, Oleksandr, Shayakhmetov, Dmitry M. , Verlinde, Christophe L. M. J. , Stehle, Thilo , McVey, John H. , Baker, Andrew H. , Peng, Kah-Whye , Roffler, Steve R. , Lieber, André , Baker, Andrew H

Mayo Clinic

Journal of Virology | August 28, 2008 | Volume: 82 | Issue: 21 | Pages: 10567-10579

10.1128/jvi.01308-08 | PMID 18753195 Get It

ABSTRACT Gene transfer vectors containing adenovirus (Ad) serotype 35 (Ad35) fibers have shown promise for cancer and stem cell gene therapy. In this study, we attempted to improve the in vitro and in vivo infection properties of these vectors by increasing their affinity to the Ad35 fiber receptor CD46. We constructed Ad vectors containing either the wild-type Ad35 fiber knob (Ad5/35) or Ad35 knob mutants with 4-fold- and 60-fold-higher affinity to CD46 (Ad5/35+ and Ad5/35++, respectively). In in vitro studies with cell lines, the higher affinities of Ad5/35+ and Ad5/35++ to CD46 did not translate into correspondingly higher transduction efficiencies, regardless of the CD46 receptor density present on cells. However, in vivo, in a mouse model with preestablished CD46 high liver metastases, intravenous injection of Ad5/35++ resulted in more-efficient tumor cell transduction. We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection.
Analysis of Finger PIP Implants
Stone, J.J., Yu, Hongrong, Linscheid, Ronald L., Cooney, William P., An, Kai‐Nan

Mayo Clinic

Advances in Bioengineering | May 16, 2008 | Volume: No volume available | Issue: No issue available | Pages: 289-290

10.1115/imece2003-43307 Get It

Total joint arthroplasty (TJA) is implemented primarily for the relief of pain, and secondarily for achieving better function by increasing the joint’s strength and motion. In order to keep health costs low, it is desirable that the TJA achieves and maintains a long-term and secure fixation of the implanted components. Unfortunately, clinical follow-up shows that the prosthetic finger implant components have long-term complications including bone resorption, wear, loosening, and failure of the implant components. Although the mechanism of complications is not fully understood, it is well known that the wear and failure of prostheses are highly related to the mechanical forces or stresses of implant components. It is therefore desirable that reliable 3-D computational finite element analysis (FEA) models can be developed and used for the stress analysis of implants. In this study, the finger proximal interphalangeal (PIP) prosthetic components were analyzed using a nonlinear finite element method. Implant components under different joint flexion angles as well as different forces were studied. The stress distribution on the contact surface of the implant component was obtained. The developed FEA models can be used to examine the contact situations (contact stress, contact region, and stress distribution), which are critical to the wear and potential failure of the implant components. Based on FEA results, the design of the current finger PIP implants can be improved for optimum performance and a long-term fixation.
Computer-Aided Design, Manufacturing, and Modeling of Polymer Scaffolds for Tissue Engineering
Stone, J.J., Thoreson, Andrew R. , Langner, Kurt L., Norton, Jay M., Stone, D.J. , Wang, Francis W., O’Driscoll, Shawn W. , An, Kai‐Nan , Langner, Kurtis L., Fitzsimmons, James S

Mayo Clinic

Manufacturing Engineering and Materials Handling, Parts A and B | April 3, 2008 | Volume: No volume available | Issue: No issue available | Pages: 169-174

10.1115/imece2005-81621 Get It

A custom computer-controlled rapid prototyping system was designed and developed in this research. This system for bio-manufacturing of polymer scaffolds included 3D motion control components, a nozzle, a pressure controller, and a temperature-controlled reservoir containing a biomaterial. Heating elements built into the reservoir melted the biomaterial. The pressure line attached to the reservoir provided a controllable force that extruded the polymer biomaterial through the nozzle and deposited the polymer biomaterial onto a platform to fabricate scaffolds. A low pressure (830 KPa) system was designed and fabricated to accommodate different temperatures, motion speeds, and viscosities of polymer biomaterials. The reservoir with the nozzle was mounted to servo motor-controlled linear x-y motion devices along with a third servo motor-controlled device that controlled the z-position of the platform. Poly(ε-caprolactone) [PCL] was used to fabricate scaffolds with designed structure that were used in cell and tissue regeneration studies. 3D computer-aided design (CAD) with Pro-Engineer and computational finite element analysis (FEA) programs with MSC_Patran and MSC_Marc were used to model scaffold designs with appropriate architecture and material selection. The CAD models were used in FEA to develop new methods for determining mechanical properties of tissue scaffolds of desired structure and geometry. FEA models were validated by mechanical testing and other published results. Technology developed in this research has potential for the advancement of bio-manufacturing, and design optimization of scaffolds for tissue engineering.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, Azra , Reeves, James A. , Feldman, Eric J. , Dewald, Gordon W., Bennett, John M. , Deeg, H. Joachim , Dreisbach, Luke, Schiffer, Charles A. , Stone, Richard M. , Greenberg, Peter L. , Curtin, Peter , Klimek, Virginia M., Shammo, Jamile M. , Thomas, Deborah A. , Schmidt, M., Wride, Kenton, Zeldis, Jerome B. , List, Alan F. , Knight, Robert

Mayo Clinic

Blood | September 25, 2007 | Volume: 111 | Issue: 1 | Pages: 86-93

10.1182/blood-2007-01-068833 | PMID 17893227 Get It

Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities. We report results of a multicenter, phase 2 trial evaluating lenalidomide therapy for transfusion-dependent patients with low- or int-1–risk MDS without deletion 5q. Eligible patients had 50 000/mm3 or more platelets and required 2 U or more RBCs within the previous 8 weeks; 214 patients received 10 mg oral lenalidomide daily or 10 mg on days 1 to 21 of a 28-day cycle. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%). Using an intention-to-treat analysis, 56 (26%) patients achieved transfusion independence (TI) after a median of 4.8 weeks of treatment with a median duration of TI of 41.0 weeks. In patients who achieved TI, the median rise in hemoglobin was 32 g/L (3.2 g/dL; range, 10-98 g/L [1.0-9.8 g/dL]) from baseline. A 50% or greater reduction in transfusion requirement occurred in 37 additional patients, yielding a 43% overall rate of hematologic improvement (TI response +‖≥ 50% reduction in transfusion requirement). Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1–risk MDS who lack the deletion 5q karyotypic abnormality. This study is registered at www.clinicaltrials.gov as no. NCT00064974.
IDOCS: Intelligent Distributed Ontology Consensus System—The Use of Machine Learning in Retinal Drusen Phenotyping
Thomas, George, Grassi, Michael A. , Lee, John R. , Edwards, Albert O., Casavant, Thomas L. , Scheetz, Todd E. , Stone, Edwin M. , Williams, Andrew B. , Gorin, Michael B. , Klein, Ronald

Mayo Clinic

Investigative Opthalmology & Visual Science | April 25, 2007 | Volume: 48 | Issue: 5 | Pages: 2278

10.1167/iovs.06-1022 | PMID 17460291 Get It

LRRK2 mutations in Parkinson disease
Farrer, Matthew J. , Stone, Jason, Mata, Ignácio F. , Lincoln, S., Kachergus, Jennifer M., Hulihan, Mary , Strain, Kari J., Maraganore, Demetrius M.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 65 | Issue: 5 | Pages: 738-740

10.1212/01.wnl.0000169023.51764.b0 | PMID 16157908 Get It

EFFECT OF CRANBERRY JUICE CONSUMPTION ON URINARY STONE RISK FACTORS
Gettman, Matthew T., Ogan, Kenneth , Brinkley, Linda, Adams‐Huet, Beverley , Pak, Charles Y.C., Pearle, Margaret S.

Mayo Clinic

Journal of Urology | July 4, 2005 | Volume: 174 | Issue: 2 | Pages: 590-594

10.1097/01.ju.0000165168.68054.f8 | PMID 16006907 Get It

Effect of Medical Management and Residual Fragments on Recurrent Stone Formation Following Shock Wave Lithotripsy
Fine, Joshua K., Pak, Charles Y.C., Preminger, Glenn M. , Segura, Joseph W., Marberger, Michael

Mayo Clinic

Journal of Urology | November 18, 2003 | Volume: 153 | Issue: 1 | Pages: 27-33

10.1097/00005392-199501000-00010 | PMID 7966783 Get It

Atorvastatin Inhibits Hypercholesterolemia-Induced Cellular Proliferation and Bone Matrix Production in the Rabbit Aortic Valve
Rajamannan, Nalini M. , Subramaniam, Malayannan , Springett, Margaret J., Sebo, Thomas, Niekrasz, Marek , McConnell, Joseph P., Stone, Neil J. , Bonow, Robert O. , Spelsberg, Thomas C., Singh, Ravinder J.

Mayo Clinic

Circulation | July 27, 2002 | Volume: 105 | Issue: 22 | Pages: 2660-2665

10.1161/01.cir.0000017435.87463.72 | PMID 12045173 Get It

Background — Despite the common occurrence of aortic stenosis, the cellular causes of the disorder are unknown, in part because of the absence of experimental models. We hypothesized that atherosclerosis and early bone matrix expression in the aortic valve occurs secondary to experimental hypercholesterolemia and that treatment with atorvastatin modifies this transformation. Methods and Results — To test this hypothesis, we developed an experimental hypercholesterolemic rabbit model. New Zealand White rabbits (n=48) were studied: group 1 (n=16), normal diet; group 2 (n=16), 1% (wt/wt) cholesterol diet; and group 3 (n=16), 1% (wt/wt) cholesterol diet plus atorvastatin (3 mg/kg per day). The aortic valves were examined with hematoxylin and eosin stain, Masson trichrome, macrophage (RAM 11), proliferation cell nuclear antigen (PCNA), and osteopontin immunostains. Cholesterol and highly sensitive C-reactive protein (hsCRP) serum levels were obtained by standard assays. Computerized morphometry and digital image analysis were performed for quantifying PCNA (% area). Electron microscopy and immunogold labeling were performed for osteopontin. Semiquantitative RT-PCR was performed for the osteoblast bone markers [alkaline phosphatase, osteopontin, and osteoblast lineage-specific transcription factor ( Cbfa-1 )]. There was an increase in cholesterol, hsCRP, PCNA, RAM 11, and osteopontin and osteoblast gene markers (alkaline phosphatase, osteopontin, and Cbfa-1 ) in the cholesterol-fed rabbits compared with control rabbits. All markers except hsCRP were reduced by atorvastatin. Conclusions — These findings of increased macrophages, PCNA levels, and bone matrix proteins in the aortic valve during experimental hypercholesterolemia provide evidence of a proliferative atherosclerosis–like process in the aortic valve associated with the transformation to an osteoblast-like phenotype that is inhibited by atorvastatin.